PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsMorphine
Morphine
Duramorph, Embeda, Infumorph, Mitigo, Morphine, Ms Contin (morphine) is a small molecule pharmaceutical. Morphine was first approved as Duramorph pf on 1984-09-18. It is used to treat dyspnea and intractable pain in the USA. The pharmaceutical is active against mu-type opioid receptor. In addition, it is known to target delta-type opioid receptor and kappa-type opioid receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
respiratory tract diseasesD012140
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Infumorph, Mitigo, Morphine, Ms contin (discontinued: Arymo, Astramorph, Avinza, Depodur, Kadian, Morphine, Oramorph)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Morphine sulfate
Tradename
Company
Number
Date
Products
MORPHINE SULFATEFresenius KabiN-204223 RX2013-10-30
3 products, RLD, RS
DURAMORPH PFHikma PharmaceuticalsN-018565 RX1984-09-18
2 products, RLD, RS
INFUMORPHHikma PharmaceuticalsN-018565 RX1991-07-19
2 products, RLD, RS
MORPHINE SULFATEHikma PharmaceuticalsN-022195 RX2008-03-17
3 products, RLD
MORPHINE SULFATEHikma PharmaceuticalsN-022207 RX2008-03-17
2 products, RLD, RS
MORPHINE SULFATEHospiraN-202515 RX2011-11-14
5 products, RLD
MS CONTINPurdue PharmaN-019516 RX1987-05-29
5 products, RLD
Show 12 discontinued
Morphine sulfate
+
Naltrexone hydrochloride
Tradename
Company
Number
Date
Products
EMBEDAAlpharmaN-022321 DISCN2009-08-13
6 products, RLD
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
avinzaNew Drug Application2011-09-22
depodur2008-01-10
duramorphNew Drug Application2024-04-09
embedaNew Drug Application2010-01-22
infumorph 200 infumorph 500New Drug Application2024-04-10
kadianNew Drug Application2011-06-15
mitigoANDA2024-09-06
morphine sulfateNew Drug Application2024-11-15
morphine sulfate extended-release2007-09-27
morphine sulfate morphine sulfateNew Drug Application2024-10-15
Show 2 more
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
dyspneaHP_0002094D004417R06.0
intractable pain—D010148—
alcoholismEFO_0003829D000437F10.1
opioid-related disordersEFO_0005611D009293F11
drug overdose—D062787—
Agency Specific
FDA
EMA
Expiration
Code
MORPHINE SULFATE, MORPHINE SULFATE, HIKMA
2024-06-02NPP
Patent Expiration
Patent
Expires
Flag
FDA Information
Morphine Sulfate, Morphine Sulfate, Fresenius Kabi Usa
90727812034-03-12DP
91926082034-03-12U-43, U-55
92482292034-03-12DP
Morphine Sulfate, Arymo Er, Zyla
90444022033-07-01DPU-1556
95498992033-07-01DPU-1556
Morphine Sulfate / Naltrexone Hydrochloride, Embeda, Alpharma Pharms
86234182029-11-07U-1640
78159342027-12-12DP
76826332027-06-19U-1510
76826342027-06-19DP
81581562027-06-19U-1510
88461042027-06-19DP
88772472027-06-19DP
86854432025-07-03U-1508
86854442025-07-03DP
Morphine Sulfate, Morphabond Er, Ohemo Life
79556192028-08-12DP
103147882028-08-12DP
ATC Codes
A: Alimentary tract and metabolism drugs
— A07: Antidiarrheals, intestinal antiinflammatory/antiinfective agents
— A07D: Antipropulsives
— A07DA: Antipropulsives
— A07DA52: Morphine, combinations
N: Nervous system drugs
— N02: Analgesics
— N02A: Opioid analgesics
— N02AA: Natural opium alkaloid analgesics
— N02AA01: Morphine
— N02AA51: Morphine, combinations
— N02AG: Opioids in combination with antispasmodics
— N02AG01: Morphine and antispasmodics
R: Respiratory system drugs
— R05: Cough and cold preparations
— R05D: Cough suppressants, excl. combinations with expectorants
— R05DA: Opium alkaloids and derivatives, cough suppressants
— R05DA05: Opium alkaloids with morphine
HCPCS
Code
Description
J0364
Injection, apomorphine hydrochloride, 1 mg
J2270
Injection, morphine sulfate, up to 10 mg
J2274
Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg
S0093
Injection, morphine sulfate, 500 mg (loading dose for infusion pump)
Clinical
Clinical Trials
1935 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Postoperative painD010149—G89.18103453136210430
PainD010146EFO_0003843R521132454563186
Multiple sclerosisD009103EFO_0003885G3561330142687
AnalgesiaD000698——134215785
SclerosisD012598——61330132585
Acute painD059787—R5261414272683
Chronic painD059350HP_0012532—51011192667
NeoplasmsD009369—C808232231664
AnesthesiaD000758——345103656
Cancer painD000072716—G89.319188943
Show 272 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
RhabdomyosarcomaD012208——784—418
SeizuresD012640HP_0002069G40.4133—1218
Major depressive disorderD003865EFO_0003761F22243—612
SchizophreniaD012559EFO_0000692F20——1—1011
SarcomaD012509——341—39
Bipolar disorderD001714EFO_0000289F30.9122—69
LeukemiaD007938—C95—24—28
Obstructive lung diseasesD008173HP_0006536—134—28
Cardiac surgical proceduresD006348———13—48
Embryonal rhabdomyosarcomaD018233——124—17
Show 58 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Post-traumatic stress disordersD013313EFO_0001358F43.1—1——89
Treatment-resistant depressive disorderD061218———1——56
Traumatic stress disordersD040921———1——56
Cognitive dysfunctionD060825HP_0001268G31.8411——35
Ewing sarcomaD012512EFO_0000173—34———5
Renal cell carcinomaD002292EFO_0000376—12——35
PancreatitisD010195HP_0001733K85—1——34
NeuroblastomaD009447EFO_0000621—23———4
Inflammatory bowel diseasesD015212EFO_0003767—12——24
Drug overdoseD062787——31——14
Show 58 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Anxiety disordersD001008EFO_0006788F41.11———45
DiseaseD004194EFO_0000408R693————3
HepatitisD006505HP_0012115K75.91———12
Pelvic painD017699——1———12
Heart arrestD006323EFO_0009492I461———12
Tibial fracturesD013978EFO_0003944S82.201———12
Fatty liverD005234EFO_0003934—1———12
Alzheimer diseaseD000544EFO_0000249F031———12
Physiological stressD013312——1————1
VasoplegiaD056987——1————1
Show 17 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HepatectomyD006498——————66
Psychotic disordersD011618—F20.81————66
Urinary bladder neoplasmsD001749—C67————44
IschemiaD007511EFO_0000556—————44
Sexual traumaD000082002——————44
Mental disordersD001523EFO_0000677F91.9————44
Liver neoplasmsD008113EFO_1001513C22.0————33
Shoulder injuriesD000070599——————33
ThoracicaD001468——————33
Knee injuriesD007718——————33
Show 221 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameMorphine
INN—
Description
Morphine is a morphinane alkaloid that is a highly potent opiate analgesic psychoactive drug. Morphine acts directly on the central nervous system (CNS) to relieve pain but has a high potential for addiction, with tolerance and both physical and psychological dependence developing rapidly. Morphine is the most abundant opiate found in Papaver somniferum (the opium poppy). It has a role as an opioid analgesic, a mu-opioid receptor agonist, a plant metabolite, an environmental contaminant, a xenobiotic, a vasodilator agent, an anaesthetic, a drug allergen and a geroprotector. It is an organic heteropentacyclic compound, a tertiary amino compound and a morphinane alkaloid. It is a conjugate base of a morphine(1+). It derives from a hydride of a morphinan.
Classification
Small molecule
Drug classOpioid
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5
Identifiers
PDB—
CAS-ID57-27-2
RxCUI—
ChEMBL IDCHEMBL70
ChEBI ID17303
PubChem CID5288826
DrugBankDB00295
UNII ID—
Target
Agency Approved
OPRM1
OPRM1
Organism
Homo sapiens
Gene name
OPRM1
Gene synonyms
MOR1
NCBI Gene ID
4988
Protein name
mu-type opioid receptor
Protein synonyms
hMOP, MOP, Mu opiate receptor, Mu opioid receptor, mu opioid receptor hMOR-1a
Uniprot ID
Q9UN57
Mouse ortholog
Oprm1 (18390)
mu-type opioid receptor (P42866)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Arymo – Zyla Life Sciences
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
Morphine
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Morphine
+
Naltrexone
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 21,258 documents
View more details
Safety
Black-box Warning
Black-box warning for: Avinza, Duramorph, Embeda, Infumorph 200 infumorph 500, Kadian, Mitigo, Morphine sulfate, Morphine sulfate morphine sulfate, Ms contin
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
152,505 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use